Withdrawals due to adverse events · Participants with Crohn's disease in remission
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (at 2 years) · Participants with Crohn's disease in remission
It is very uncertain whether infliximab changes serious adverse events (at 2 years) compared with purine analogues (very low certainty).
1 finding from 1 review
Serious adverse events (at 52 weeks) · patients with Crohn's disease (with mixed/low disease activity at baseline)
Infliximab showed no clear difference in serious adverse events (at 52 weeks) compared with biosimilar (low certainty).
1 finding from 1 review
Serious adverse events (at 56 weeks) · patients with Crohn's disease (active disease population with clinical response at baseline)
It is very uncertain whether infliximab changes serious adverse events (at 56 weeks) compared with adalimumab (very low certainty).
1 finding from 1 review
Serious adverse events (at 54 weeks) · patients with Crohn's disease (mixed disease activity population with clinical response at baseline)
It is very uncertain whether infliximab changes serious adverse events (at 54 weeks) compared with placebo (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with Crohn's disease (with mixed/low disease activity at baseline)
Infliximab may leads to higher withdrawal due to adverse events (at 52 weeks) compared with biosimilar (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with Crohn's disease (active disease population with clinical response at baseline)
It is very uncertain whether infliximab changes withdrawal due to adverse events (at 56 weeks) compared with adalimumab (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with Crohn's disease (mixed disease activity population with clinical response at baseline)
It is very uncertain whether infliximab changes withdrawal due to adverse events (at 32‐54 weeks) compared with placebo (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active Crohn's disease
The review found no eligible studies for this question.
2 findings from 1 review
Withdrawals due to adverse events · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · Patients with active Crohn's disease
Azathioprine + infliximab showed no clear difference in adverse events compared with infliximab (moderate certainty).
1 finding from 1 review
Adverse events · maintenance of remission in Crohn's disease
It is very uncertain whether azathioprine and infliximab changes adverse events compared with infliximab (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active Crohn's disease
Infliximab 5 mg/kg showed no clear difference in withdrawals due to adverse events compared with purine analogues (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active Crohn's disease
Infliximab 5 mg/kg showed no clear difference in withdrawals due to adverse events compared with CT‐P13 biosimilar 5 mg/kg (low certainty).
1 finding from 1 review
Serious adverse events · Patients with active Crohn's disease
Azathioprine + infliximab probably leads to lower serious adverse events compared with infliximab (moderate certainty).
1 finding from 1 review
Serious adverse events · maintenance of remission in Crohn's disease
It is very uncertain whether azathioprine and infliximab changes serious adverse events compared with infliximab (very low certainty).
1 finding from 1 review
Adverse events (Schröder 2006) · adult patients with refractory Crohn's disease
It is very uncertain whether methotrexate + infliximab changes adverse events (Schröder 2006) compared with infliximab alone (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active Crohn's disease
Azathioprine + infliximab showed no clear difference in withdrawals due to adverse events compared with infliximab (moderate certainty).
1 finding from 1 review
Adverse events up to week 10 · Participants with active Crohn's disease despite current treatment with infliximab
Three infusions of natalizumab (300 mg) and two infusions of… showed no clear difference in adverse events up to week 10 compared with placebo and two infusions of infliximab (moderate certainty).
1 finding from 1 review